Who are Trexall's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methotrexat.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Trexall — Competitive Intelligence Brief

Trexall (methotrexate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate, DMARD. Area: Oncology.

marketed Antifolate, DMARD Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trexall (methotrexate) — Generic (originally Lederle Laboratories). Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trexall TARGET	methotrexate	Generic (originally Lederle Laboratories)	marketed	Antifolate, DMARD	Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4	1953-12-07
Methotrexat	Methotrexat	Biocad	marketed		Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-04 — Trexall · 8021335 · Formulation · US
2029-03-10 — Trexall · 11684723 · Formulation · US
2029-03-10 — Trexall · 9867949 · Formulation · US
2029-03-10 — Trexall · 10709844 · Formulation · US
2029-06-01 — Trexall · 8664231 · Method of Use · US
2030-03-19 — Trexall · 12357642 · Formulation · US
2030-03-19 — Trexall · 11497753 · Formulation · US
2030-03-19 — Trexall · 9421333 · Formulation · US
2030-03-19 — Trexall · 8579865 · Formulation · US
2030-03-19 — Trexall · 8945063 · Formulation · US
2030-03-19 — Trexall · 8480631 · Formulation · US
2031-05-27 — Trexall · 8814834 · Formulation · US
2034-10-29 — Trexall · 11771701 · Formulation · US
2035-10-28 — Trexall · 11129833 · Formulation · US

Sponsor landscape (Antifolate, DMARD class)

Generic (originally Lederle Laboratories) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trexall — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab